NASDAQ: PTN
Palatin Technologies, Inc.
Healthcare · Biotechnology
After hours: $11.00(+4.96%) · as of 6:38 PM ET
Market Cap
$18.65M
52w High
$31.00
52w Low
$5.61
P/E
-2.25
Volume
128.99K
Outstanding Shares
1.78M
Valuation Data Insufficient
Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.
Performance
Return analysis
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock rose 2.64% over the last year. Revenue grew 3,581.22% over the trailing twelve months. Operating margin moved from -6,718.52% to -50.6%. Free cash flow grew 36.76% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -50.6%. A decisive move in revenue — currently up 3,581.22% — would be the clearest signal to resolve the ambiguity.
Company profile
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.
Valuation
Stock splits
Every 50 shares became 1
Every 25 shares became 1
Every 10 shares became 1
Every 4 shares became 1
Every 10 shares became 1
Profitability & growth
Analyst consensus
3
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Sep 2, 2026
Q3 FY26 · EPS est -$1.20 · Revenue est $1.5M
View